Editing Away Autoimmunity at the HLA Source

What It Covers

Rheumagen CEO Richard Fried explains how the company's HLA gene editing platform targets the genetic root of autoimmune diseases. Rather than suppressing the immune system broadly, Rheumagen edits a single amino acid position in hematopoietic stem cells to permanently silence disease-triggering antigen presentation, beginning with rheumatoid arthritis.

Key Questions Answered

• •Anchor Editing Strategy: Rheumagen's platform targets asparagine at position 82, a conserved site present across all HLA class II alleles. Swapping this amino acid disrupts hydrogen bonding required for peptide presentation, effectively silencing one disease-linked HLA allele while leaving the remaining 11–12 alleles intact to maintain normal immune defense against pathogens.
• •Non-Myeloablative Outpatient Delivery: Unlike traditional bone marrow transplants requiring full myeloablation, Rheumagen's ex vivo stem cell editing requires only minimal bone marrow space-clearing. The therapy is designed for outpatient infusion centers—similar to where RA patients receive biologic infusions—reducing procedural risk and cost compared to hospital-based cell and gene therapy protocols.
• •Tipping Point Threshold for Cure: Full stem cell replacement is not required for clinical benefit. Replacing approximately 90% of hematopoietic stem cells likely produces equivalent disease reduction, and a residual low-level T cell signal can become tolerogenic—essentially training the immune system to ignore self-antigens—potentially crossing a threshold to complete, medication-free remission.
• •Regulatory Platform Designation Pathway: Because anchor editing targets the same position 82 across all indications, the FDA's platform designation allows Rheumagen to demonstrate safety once in humans, then advance directly to Phase 2 efficacy trials in subsequent indications including MS and type 1 diabetes, bypassing repeated Phase 1 safety work for each disease.
• •Economic Disruption of Chronic Care Spend: RA patients currently spend $50,000–$60,000 annually on biologics alone, with 60% never reaching remission and 20–30% classified as refractory after failing multiple drugs. A one-time curative therapy with a two-to-four-year payer payback period replaces ongoing chronic spend, repositioning the therapy as a healthcare investment rather than an incremental cost.